Jaguar Health And Magdalena Biosciences Executes Out-License Deal With For Botanical Drug Candidate for Schizophrenia
Portfolio Pulse from Benzinga Newsdesk
Jaguar Health and Magdalena Biosciences have executed an out-license deal for a botanical drug candidate for schizophrenia. The drug shows antipsychotic activity with a unique mechanism of action. Jaguar will receive milestone payments and increasing royalties upon commercialization in the U.S. schizophrenia market, projected to reach $8.06 billion by 2030.
May 29, 2024 | 12:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Jaguar Health has entered into an out-license deal with Magdalena Biosciences for a botanical drug candidate for schizophrenia. Jaguar will receive milestone payments and royalties upon commercialization in the U.S. market, which is expected to reach $8.06 billion by 2030.
The out-license deal positions Jaguar Health to benefit financially from milestone payments and royalties as the drug candidate progresses towards commercialization. The U.S. schizophrenia market's significant growth potential further enhances the positive impact on Jaguar's revenue prospects.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100